Wall Street’s biotech and medtech set is quietly stitching together a new playbook for chronic disease – one that blends Phase 3 data, insulin hardware, boardroom star power, and China oncology.
Ulcerative Colitis: Abivax Steps Onto Center Stage
French biotech Abivax SA…
